ADMS News and Press, Adamas Pharmaceuticals Inc. From 08/07/20

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Gainers:  Conduent (NASDAQ: CNDT ) +75% . More news on: Conduent Incorporated, OpGen, Inc., Groupon, Inc., Stocks on the move, , Read more ...

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2020 Earnings Conference Call August 7, 2020 4:30 PM Company Participants Peter Vozzo – Investor Relations Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss – Chi...

Adamas Pharma (NASDAQ: ADMS ) : Q2 GAAP EPS of -$0.37 beats by $0.24 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019 Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019 EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS...

EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conf...

Adamas Pharmaceuticals ( ADMS +4.5% )  announces new post-hoc Phase 3 data showing that Gocovri decreased dyskinesia and OFF time (periods where levodopa therapy is not working well) in people with Parkinson’s Disease (PD). More news on: Adamas Pharmaceuticals, Inc., He...

EMERYVILLE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced its presentation of a new post-hoc pivo...

Xeris Pharma Reports Positive Topline Data for Insulin Trial Xeris Pharmaceuticals ( XERS ) reported positive data for its Phase 2 clinical trial for diabetes. The drug candidate XP-3924 is an o-formulation of pramlintide and insulin and the trial aimed to assess its potential in treati...

Gainers:  ELOX +52.1% . ORN +17.7% . TMBR +8.5% . ABM +8.0% . DADA +7.2% . More news on: Eloxx Pharmaceuticals, Inc., Orion Group Holdings, Inc., Timber Pharmaceuticals, Inc., Stocks on the move, , Read more ...